N2-环丙基-5-硝基吡啶-2-胺 | 246862-51-1

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: N2-环丙基-5-硝基吡啶-2-胺
• 英文名称: N-cyclopropyl-5-nitropyridin-2-amine
• CAS: 246862-51-1
• 化学式: C₈H₉N₃O₂
• mdl: MFCD00097476
• 分子量: 179.178
• InChiKey: MVTPBGCAEZTYHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  70.7
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  N2-环丙基-5-硝基吡啶-2-胺 在 palladium 10% on activated carbon 、 氢气 作用下， 以 二氯甲烷 为溶剂， 生成 N2-cyclopropyl-pyridine-2,5-diamine
  参考文献：
  名称：

  N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy

  摘要：

  A series of N-pyridyl benzamide KCNQ2/Q3 potassium channel openers were identified and found to be active in animal models of epilepsy and pain. The best compound 12 [ICA-027243, N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide] has an EC(50) of 0.38 mu M and is selective for KCNQ2/Q3 channels. This compound was active in several rodent models of epilepsy and pain but upon repeated dosing had a number of unacceptable toxicities that prevented further development. On the basis of the structure activity relationships developed around 12, a second compound, 51, [N-(2-chloro-pyrimidin-5-yl)-3,4-difluoro-benzamide, ICA-069673], was prepared and advanced into a phase 1 clinical study. Herein, we describe the structure activity relationships that led to the identification of compound 12 and to the corresponding pyrimidine 51.

  DOI：

  10.1021/ml200053x

文献信息

• Diacylglycerol acyltransferase inhibitors
  申请人：Bolin Robert David

  公开号：US20070123504A1

  公开（公告）日：2007-05-31

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

  本文提供了式(I)的化合物，以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗诸如肥胖、2型糖尿病和代谢综合征等疾病是有用的。
• DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS
  申请人：Bolin David Robert

  公开号：US20100190979A1

  公开（公告）日：2010-07-29

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

  本文提供了以下式(I)的化合物及其药学上可接受的盐，其中取代基如规范中所述。这些化合物及含有它们的药物组成物，可用于治疗疾病，例如肥胖症、2型糖尿病和代谢综合征。
• Diacylglycerol Acyltransferase Inhibitors
  申请人：Bolin David Robert

  公开号：US20100168419A1

  公开（公告）日：2010-07-01

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

  本文所提供的化合物具有公式（I）的结构，以及其药学上可接受的盐，其中取代基与规范中所披露的相同。这些化合物以及含有它们的制药组合物，可用于治疗疾病，例如肥胖症、2型糖尿病和代谢综合征。
• THERAPEUTIC QUINAZOLINE DERIVATIVES
  申请人：AstraZeneca AB

  公开号：EP1218355A1

  公开（公告）日：2002-07-03
• PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS
  申请人：AstraZeneca AB

  公开号：EP1831198A1

  公开（公告）日：2007-09-12